I think you read updates to the brief today based on this new entry - but I will re-iterate to see notes from today. Interesting but a little off with focus we asked to be on U and I and simple enough to see the word when looking at it. See updated brief under comments. I think these are nice but too subtle and the hexagon has lost favor for the design with the comments added today after a team meeting.
I would say that feedback was on less focus on hexagon, more focus on the U and the I or even tying them together somehow, making them stand out as a combo....We decided to use GENUINE or another name RUBICON for our first trial and UNITY for a different trial (combines Ublituximab and TGR-1202 for U and T).
That said however - for GENUINE - remember the importance of the U and the I being key. We like the word and what it stands for - we see the chance to highlight "our" drug with "U" (an antibody) and the idea of a combo with the I drug (a BCR receptor inhibitor of BTK - less important). Maybe even tying them together somehow. Please see the updated comments at brief about that and also about focusing on the science behind the drugs possibly (shapes of the pathways inhibited - search antiCD20 antibody or BCR receptor) in the logo or any design element. It is valuable feedback from our CEO, COO and team to make a decision with me. THANKS AGAIN!